In the ever-evolving landscape of pediatric cardiology, a groundbreaking study has emerged, casting new light on the enigmatic and severe hypertrophic cardiomyopathy (HCM) associated with RASopathies. These rare genetic disorders, caused by activating mutations in the RAS-MAPK signaling pathway, represent a unique subset of pediatric HCM cases marked by a particularly aggressive clinical course. Despite their significant impact, therapeutic options have remained limited, with existing treatments primarily targeting the broader HCM population. The innovative research led by Ruiz-Velasco et al., published in Pediatric Research, has set out to unravel the functional and energetic underpinnings of RASopathy-associated HCM and to assess the potential therapeutic promise of mavacamten—a myocardial myosin inhibitor already revolutionizing treatment in obstructive HCM.
The RAS-MAPK pathway plays a critical role in cell proliferation, differentiation, and survival. Aberrant activation of this signaling cascade causes a spectrum of developmental disorders collectively known as RASopathies, which frequently manifest with cardiac abnormalities, including hypertrophic cardiomyopathy. Approximately 20% of pediatric HCM cases can be traced back to mutations within this pathway, signifying a substantial subset of patients with distinct pathophysiology and prognosis. Notably, these patients exhibit poorer outcomes compared to traditional sarcomeric HCM, underscoring the urgent need for targeted therapies.
Mavacamten, celebrated for its ability to modulate cardiac contractility by selectively inhibiting cardiac myosin ATPase, has reshaped clinical management in obstructive HCM. By attenuating hypercontractility and restoring hemodynamic balance, mavacamten improves symptoms and reduces left ventricular outflow tract obstruction. However, until now, its efficacy had not been explored in the context of RASopathy-associated HCM, a disease variant hypothesized to involve divergent molecular mechanisms beyond sarcomeric dysfunction.
To bridge this crucial knowledge gap, Ruiz-Velasco and colleagues developed a pre-clinical in vitro model that faithfully recapitulates the cellular environment of RAS-MAPK mutation-driven HCM. Employing induced pluripotent stem cell-derived cardiomyocytes harboring specific activating mutations, the team meticulously characterized contractile behavior, bioenergetic parameters, and electrophysiological features. This model enabled an unprecedented exploration of how pathological signaling pathways converge on myocardial mechanics and energy metabolism.
Their findings reveal profound disturbances in both the functional output and energetic state of RASopathy cardiomyocytes. Notably, the mutant cardiomyocytes demonstrated marked hypercontractility coupled with maladaptive calcium handling—hallmarks reminiscent of sarcomeric HCM but accompanied by distinct mitochondrial dysfunction. These energy deficits manifested as diminished ATP production and altered substrate utilization, hinting at a complex interplay between signaling-driven hypertrophy and metabolic derangements.
Intriguingly, treatment with mavacamten significantly ameliorated these aberrations. The drug’s myosin-inhibitory activity yielded a normalization of contractile force and an improvement in calcium cycling dynamics. Beyond mechanical effects, mavacamten also rescued energetic imbalances, restoring mitochondrial activity and ATP synthesis toward physiological levels. These dual effects suggest that mavacamten’s benefits extend beyond mechanical modulation, potentially addressing foundational bioenergetic impairments in RASopathy HCM.
The implications of this study are manifold. First, it establishes a robust experimental platform to dissect the molecular pathology of RAS-MAPK driven cardiomyopathies. Second, it highlights the potential of mavacamten as a therapeutic agent beyond its current indication, opening avenues for repurposing in pediatric populations with genetically distinct cardiomyopathies. This is particularly compelling given that existing clinical trials for mavacamten have systematically excluded patients with RASopathies, leaving a critical void in evidence.
Importantly, these findings prompt a reevaluation of the mechanistic paradigms underlying RASopathy-associated HCM. The intersection of aberrant signaling cascades with sarcomeric hypercontractility and metabolic dysfunction suggests a multifaceted disease process, requiring integrated therapeutic strategies. Mavacamten’s dual impact on mechanical and energetic defects may represent a prototype for such approach, potentially improving patient outcomes that have historically been dismal.
Moreover, the study advocates for precision medicine frameworks in pediatric cardiology, wherein genetic diagnosis guides therapeutic decision-making. With the advent of comprehensive genomic profiling, identifying patients with RAS-MAPK mutations at diagnosis is becoming increasingly feasible. Consequently, incorporating mavacamten or similar agents into tailored treatment regimens could revolutionize care standards and prognosis for affected children.
Despite the transformative potential, the research also cautions about the necessity for clinical validation through carefully designed trials. Pre-clinical models, while informative, cannot fully capture the systemic complexities and safety considerations in vivo. Future investigations will need to assess long-term efficacy, optimal dosing, and possible side effects of mavacamten in pediatric cohorts, particularly given developmental considerations inherent to this population.
Further, the study sparks interest in exploring additional therapeutic targets within the RAS-MAPK pathway and downstream metabolic networks. Combination therapies that simultaneously modulate signaling, contractility, and metabolism might offer synergistic benefits, addressing the multifactorial nature of RASopathy cardiomyopathy. The integration of cutting-edge omics technologies and patient-derived cellular models will be critical to identifying such novel interventions.
The translational impact of this research is timely. Pediatric hypertrophic cardiomyopathy remains a leading cause of sudden cardiac death and heart failure in children, with RASopathy cases posing a disproportionate clinical challenge. Innovations that improve energy balance and cardiac function in this subgroup have the potential to dramatically alter disease trajectory and quality of life for young patients and their families.
In conclusion, the study by Ruiz-Velasco and colleagues represents a significant advance in our understanding of pediatric RASopathy-associated hypertrophic cardiomyopathy. By demonstrating that mavacamten ameliorates both contractile and energetic abnormalities in a pre-clinical model, it opens promising therapeutic horizons that may soon transition from bench to bedside. As the field moves toward more nuanced and effective treatments, this research serves as a beacon illuminating the path forward in the fight against this devastating pediatric disease.
Subject of Research: Pediatric hypertrophic cardiomyopathy associated with activating mutations in the RAS-MAPK pathway and the therapeutic potential of mavacamten.
Article Title: Mavacamten improves energy balance in a pre-clinical model of RASopathy-associated hypertrophic cardiomyopathy.
Article References: Ruiz-Velasco, A., Jouve, C., Deshayes, L. et al. Mavacamten improves energy balance in a pre-clinical model of RASopathy-associated hypertrophic cardiomyopathy. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05208-9
Image Credits: AI Generated
DOI: 22 June 2026
Tags: clinical outcomes in genetic hypertrophic cardiomyopathyfunctional energetics of RASopathy heart diseasemavacamten treatment for hypertrophic cardiomyopathymyocardial myosin inhibitors in cardiologynovel treatments for RASopathy cardiac manifestationspediatric cardiology advancements in HCMRAS-MAPK signaling pathway mutationsRASopathy-associated pediatric hypertrophic cardiomyopathysarcomeric vs non-sarcomeric hypertrophic cardiomyopathytargeted therapies for rare genetic heart disorders
